Journal of the American Academy of Dermatology · 2026
Sequential small-molecule therapy for lymphocytic cicatricial alopecia: A multicenter prospective cohort pilot study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Yanhua, Shao Guanghui, Tao Qiuwei, Li Yuqian, Wang Yizhou, Zhu Qilin, Zhu Jing, Qiu Sangsang, Li Zhongming, Wang Yanyun, Du Xufeng
Аннотация
BACKGROUND: Lymphocytic cicatricial alopecia (LCA) is a rare disorder causing irreversible hair follicle stem cell damage, with limited evidence supporting systemic treatments.
OBJECTIVE: To assess the efficacy and safety of a predefined three-stage sequential small-molecule therapy for active LCA.
METHODS: This multicenter prospective cohort pilot study enrolled adults with histopathologically confirmed active LCA at 3 Chinese tertiary centers. The regimen included oral Tofacitinib + topical Crisaborole (Stage I), oral Apremilast + topical Crisaborole (Stage II), and topical Crisaborole alone (Stage III). Primary outcomes were longitudinal Lichen Planopilaris Activity Index (LPPAI) and its improvement rate (ILPPAIS%).
RESULTS: Of 33 patients, 31 completed the regimen. Baseline LPPAI (5.65 ± 1.45) decreased significantly to 0.75 ± 0.27 (ILPPAIS% 85.5%, P < .001) at Stage III; 93.5% achieved marked improvement with only 3 mild adverse events.
LIMITATIONS: Small sample size, lack of control group, and short follow-up.
CONCLUSION: In this patient cohort, three-stage sequential regimen was well tolerated and offers a promising treatment option for active LCA.
OBJECTIVE: To assess the efficacy and safety of a predefined three-stage sequential small-molecule therapy for active LCA.
METHODS: This multicenter prospective cohort pilot study enrolled adults with histopathologically confirmed active LCA at 3 Chinese tertiary centers. The regimen included oral Tofacitinib + topical Crisaborole (Stage I), oral Apremilast + topical Crisaborole (Stage II), and topical Crisaborole alone (Stage III). Primary outcomes were longitudinal Lichen Planopilaris Activity Index (LPPAI) and its improvement rate (ILPPAIS%).
RESULTS: Of 33 patients, 31 completed the regimen. Baseline LPPAI (5.65 ± 1.45) decreased significantly to 0.75 ± 0.27 (ILPPAIS% 85.5%, P < .001) at Stage III; 93.5% achieved marked improvement with only 3 mild adverse events.
LIMITATIONS: Small sample size, lack of control group, and short follow-up.
CONCLUSION: In this patient cohort, three-stage sequential regimen was well tolerated and offers a promising treatment option for active LCA.